Author:
Hohlfeld Thomas,Twarock Sören
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Newby LK, Hasselblad V, Armstrong PW et al (2003) Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. Eur Heart J 24:182
2. Twarock S, Bagheri S, Bagheri S et al (2016) Platelet-vessel wall interactions and drug effects. Pharmacol Ther 167:74
3. Majithia A, Bhatt DL (2019) Novel antiplatelet therapies for atherosclerotic diseases. Arterioscler Thromb Vasc Biol 39:546
4. Zeymer U, Hohlfeld T, vom Dahl J et al (2017) Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i.v. and 300 mg p.o. in ACS (ACUTE). Thromb Haemost 117:625
5. Valgimigli M, Bueno H, Byrne RA et al (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 389:213